Precious Metals Chemistry is a constantly evolving business unit. And we are happy to inform you here on our most important changes and novelties.
Please feel free to contact us for more information!
June 23, 2017 - Umicore inaugurates new production facility in Germany
Umicore’s business unit Precious Metals Chemistry inaugurated today its innovative production unit for advanced metal organic precursor technologies used in the semiconductor and LED markets, respectively TMGa (Trimethylgallium) and TEGa (Triethylgallium). The event was attended by European and overseas customers as well as local and regional politicians. The guest of honour was Dr. Barbara Hendricks, Germanys Federal Minister for the Environment, Nature Conservation, Building and Nuclear Safety.
Umicore’s TMGa manufacturing process is innovative and unique. It offers a more sustainable and ecological production method by minimizing hazardous side streams and material losses and optimizing yield to nearly 100%. This makes it superior to all existing manufacturing methods in the industry.
Dr Lothar Mussmann, Vice-President of Umicore Precious Metals Chemistry said “I am proud that this patented innovation has now become a world-class and industrial scale manufacturing plant. It will provide benefits for our customers and the environment and underlines Umicore’s position as a pioneer in sustainable technologies.
March 27, 2017 - Umicore’s Argentinian facility for anticancer APIs passes new European GMP audit
Umicore’s API (Active Pharmaceutical Ingredients) facility in Pilar, Buenos Aires, successfully underwent a European GMP (Good Manufacturing Practice) inspection by the German Health and Medicine Authority. The success of this new audit confirms Umicore ability to manufacture highly potent anticancer APIs at highest quality standards and to sell them in Europe.
Michael Schwarz, Director Global API Business, comments: “This is an important success for Umicore’s activities in highly potent anticancer APIs. It follows a number of successful inspections by international customers and health authorities and it shows that our manufacturing site has fully integrated the principles and guidelines of good manufacturing practices. This will strongly support our further growth in the European market.”
Umicore´s facility in Pilar opened in 2009 and manufactures cisplatin, carboplatin, oxaliplatin and arsenic(III) oxide for global markets, based on current international guidelines. It also exclusively produces a number of high quality proprietary highly potent APIs. Umicore’s API business offers professional services – such as exclusive hAPI development and manufacturing, IP and regulatory support, quality assurance and quality control – and highly competitive business terms. Umicore is committed to further develop the facility to be able to provide the first class products and services its global customers will need in future.
December 12, 2016 - Umicore rebranding is online
We are proud to announce the successful Go-Live of Umicore's new brand image and Precious Metals Chemistry's renewed website. Our customers and partners now benefit from even more online technical product and service information. Please contact us if you miss the information you are looking for.